Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
Arboretum Ventures is the famous VC, which was founded in 2002. The venture was found in North America in United States. The main office of represented VC is situated in the Ann Arbor.
The current fund was established by Jan Garfinkle, Tim Petersen. We also calculated 4 valuable employees in our database.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Arboretum Ventures, startups are often financed by Chrysalis Ventures, Lumira Ventures, ONSET Ventures. The meaningful sponsors for the fund in investment in the same round are Chrysalis Ventures, Baird Capital, ONSET Ventures. In the next rounds fund is usually obtained by Lumira Ventures, ONSET Ventures, Flagship Pioneering.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Considering the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Arboretum Ventures performs on 9 percentage points less the average number of lead investments. The important activity for fund was in 2013. Despite it in 2019 the fund had an activity.
Among the most successful fund investment fields, there are Medical, Hospital. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Cardiac Dimensions, NeuMoDx Molecular, Delphinus Medical Technologies.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Boomerang Medical | $15M | 01 Nov 2022 | Mountain View, California, United States | ||
Delphinus Medical Technologies | $30M | 13 Sep 2022 | Michigan, United States | ||
Navv Systems | $5M | 18 Aug 2022 | Detroit, Michigan, United States | ||
Enumera Molecular | $12M | 05 May 2022 | Ann Arbor, Michigan, United States | ||
Koya Medical | $26M | 03 Feb 2022 | Oakland, California, United States | ||
ViaLase | $27M | 19 Nov 2021 | Corona Del Mar, California, United States | ||
Convergent Dental | $40M | 29 Oct 2021 | Massachusetts, United States | ||
Boomerang Medical | $3M | 18 Oct 2021 | Mountain View, California, United States | ||
Akadeum Life Sciences | $17M | 12 Oct 2021 | Ann Arbor, Michigan, United States |
– Convergent Dental, a Needham, MA-based developer of a laser to enable anesthesia-free, pain-free dentistry, raised $40m in Series C round.
– The round was led by Arboretum Ventures, with participation from existing investors, including Long River Ventures and the Gund Foundation.
– The new investment will be used to expand the company’s product portfolio and increase investment in market development.
– Francis Medical, a Minneapolis MI-based medical device company, raised $55M in Series B equity funding.
– The round was led by Solas BioVentures with participation from Arboretum Ventures, Coloplast A/S, H2Oey Ventures and Tonkawa.
– The company intends to use the funds to fund for the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
